This invention discloses a nutritional composition of matter that effectively provide a nootropic effect beyond the effects simple obtain by cannabinoids alone. Effectively reduce anxiety due to ingestion of xanthines containing oral products. Similarly reduce the side effects associated with the exogenous ingestion of yohimbine and its derivatives.

This invention discloses a nutritional composition of matter that effectively provide a nootropic effect beyond the effects simple obtain by cannabinoids alone. Effectively reduce anxiety due to ingestion of xanthines containing oral products. Similarly reduce the side effects associated with the exogenous ingestion of yohimbine and its derivatives.

The present invention relates to a composition for enhancing immunity or a composition for preventing or ameliorating neurodegenerative diseases, both of which contain, as an active ingredient, a mixture extract of goji berries, mulberries and jujubes or an extract mixture thereof.

This invention relates to the use of a nutritional composition comprising sialylated oligosaccharides for enhancing cognitive development and learning skills in mammals. The nutritional composition comprises 3′-Siallylactose (3′-SL) and 6′-Siallylactose (6′-SL) in a weight ratio between 10:1 and 1:10 and is specifically for use in enhancing learning skills and/or enhancing memory function in an individual by increasing the sialic acid (Neu5Ac) concentration in the brain of said individual.

This invention relates to the use of a nutritional composition comprising sialylated oligosaccharides for enhancing cognitive development and learning skills in mammals. The nutritional composition comprises 3′-Siallylactose (3′-SL) and 6′-Siallylactose (6′-SL) in a weight ratio between 10:1 and 1:10 and is specifically for use in enhancing learning skills and/or enhancing memory function in an individual by increasing the sialic acid (Neu5Ac) concentration in the brain of said individual.

The present disclosure relates to a composition for improving sleep quality, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof. The composition for improving sleep quality may improve the sleep quality by increasing melatonin secretion. In addition, in another aspect, the present disclosure provides a composition for alleviating stress, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof.

The present disclosure relates to a composition for improving sleep quality, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof. The composition for improving sleep quality may improve the sleep quality by increasing melatonin secretion. In addition, in another aspect, the present disclosure provides a composition for alleviating stress, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof.

The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises a combination of paraxanthine and tyrosine and/or taurine and optionally other compounds that modulate the effects of a combination of paraxanthine and tyrosine and/taurine. Further disclosed are methods of use of the foregoing compositions for improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite.

The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises a combination of paraxanthine and tyrosine and/or taurine and optionally other compounds that modulate the effects of a combination of paraxanthine and tyrosine and/taurine. Further disclosed are methods of use of the foregoing compositions for improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite.

Aspects of the present disclosure include fatty acid β-hydroxyester compounds (e.g., fatty acid esters of β-hydroxybutyrate), fatty acid esters of butanediol, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions having one or more fatty acid β-hydroxyester compounds and/or one or more fatty acid esters of butanediol. Methods for treating a subject by administering one or more esters to the subject are also provided. Kits containing one or more of the subject esters are also described.